US EditionPublished • loading... • Updated
Doctors without Borders: Inadequate Access to Lenacapavir Hiv Prophylaxis
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
New York/Berlin — The aid organization Doctors Without Borders is demanding that the US pharmaceutical company Gilead Sciences be able to directly purchase the long-effective HIV prophylaxis lenacapavir. The attempt to buy a limited quantity of the capsid inhibitor directly for use in their own programs was rejected by the company, criticizes...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
